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Abstract
Background: 5-fluorouracil remains the standard therapy for patients with advanced/metastatic
colorectal cancer. Pre-clinical studies have demonstrated the biological modulation of 5-
fluorouracil by methotrexate and leucovorin. This phase II study was initiated to determine the
activity and toxicity of sequential methotrexate – leucovorin and 5-fluorouracil chemotherapy in
patients with advanced colorectal cancer.
Methods: Ninety-seven patients with metastatic colorectal cancer were enrolled onto the study.
Methotrexate – 30 mg/m2 was administered every 6 hours for 6 doses followed by a 2 hour infusion
of LV – 500 mg/m2. Midway through the leucovorin infusion, patients received 5-fluorouracil – 600
mg/m2. This constituted a cycle of therapy and was repeated every 2 weeks until progression.
Results: The median age was 64 yrs (34–84) and the Eastern Cooperative Group Oncology
performance score was 0 in 37%, 1 in 55% and 2 in 8% of patients. Partial and complete responses
were seen in 31% of patients with a median duration of response of 6.4 months. The overall median
survival was 13.0 months. The estimated 1-year survival was 53.7%. Grade III and IV toxic effects
were modest and included mucositis, nausea and vomiting.
Conclusions: This phase II study supports previously reported data demonstrating the modest
clinical benefit of 5-FU modulation utilizing methotrexate and leucovorin in patients with metastatic
colorectal cancer. Ongoing studies evaluating 5-fluorouracil modulation with more novel agents
(Irinotecan and/or oxaliplatin) are in progress and may prove encouraging.
Background
Although a number of recently introduced chemothera-
peutic agents have demonstrated significant anti-tumor
activity in advanced colorectal cancer, [1–9] standard
therapy for patients with metastatic disease remains 5-
fluorouracil (5-FU) – based chemotherapy.[10] A vast se-
ries of pre-clinical and clinical studies have suggested 5-
FU is a more active anti-tumor agent when modulated by
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a host of compounds including leucovorin, [11–13]
methotrexate,[14] folinic acid, [15,16] N-phospho-
nacetyl-L-aspartic acid (PALA) [17–22] and recombinant
interferon alfa-2a (IFNaα -2a). [23,24] Protracted venous
infusion (PVI) 5-FU regimens have also resulted in in-
creased response rates in some studies, but only results in
a modest benefit in median survival. [25,26] Oral fluoro-
pyrimidines and oral regimens using prodrugs of 5-FU or
inhibitors of dihydropyrimidine dehydrogenase (DPD)
which pharmacologically simulate the intravenous con-
tinuous infusion administration of 5-FU are currently un-
der clinical evaluation. Although these studies are
important and may demonstrate equivalency, it is not
clear these oral compounds will result in a significant im-
provement compared to the intravenous infusion of 5-
FU.[27]
Potentiation of the anti-tumor activity of 5-FU by meth-
otrexate (MTX) and leucovorin (LV) requires careful
scheduling to achieve the most favorable interactions be-
tween these 3 drugs. In vitro and in vivo studies have both
suggested a synergistic as well as antagonistic effect when
5-FU, MTX and LV are used in combination. [28–32] In
this report, two modulators of 5-FU were used in a se-
quential manner, anticipating an enhancement of the ef-
ficacy of 5-FU before the development of 5-FU resistance
and subsequent disease progression. The order of admin-
istration of the three agents was chosen to optimally ex-
ploit the reported differing mechanisms of biochemical
modulation. The objectives of this phase II study were to
determine the activity and toxicity of MTX/LV/5-FU in pa-
tients with advanced colorectal cancer.
Patients and Methods
Between August of 1987 and August of 1988, 97 patients
with advanced colorectal cancer were enrolled onto this
study. Informed consent was obtained in writing from all
patients according to Institutional Review Board guide-
lines. Eligibility criteria included histologic proof of met-
astatic colorectal carcinoma and the presence of at least
one bidimensionally measurable lesion on computed to-
mography scan. All patients were required to have an East-
ern Cooperative Oncology (ECOG) Group performance
score of 0 – 2 and have a life expectancy greater than 2
months. Patients also were required to meet the following
criteria: adequate bone marrow, renal, and hepatic func-
tion as evidenced by a white blood cell count = 4,000
cells/ul, platelet count = 100,000 cells/ul, creatinine = 2.0
mg/dl or creatinine clearance of 60 ml/min and a serum
bilirubin = 1.5 mg/dl and no serious intercurrent medical
or mental illness. Patients could not have received prior
chemotherapy (excluding adjuvant chemotherapy).
Treatment Plan
Consistent with the traditional design of phase II studies,
all patients received therapy as outlined in the treatment
schema in figure 1. Methotrexate was administered at a
dose of 30 mg/m2 orally every 6 hours on an empty stom-
ach for 6 doses. At hour 36 a 2 hour intravenous infusion
of leucovorin was administered at a dose of 500 mg/m2.
Midway through the leucovorin infusion, 5-FU at a dose
of 600 mg/m2 was given as a 30 minute intravenous bolus
infusion. This represented a course of therapy and was re-
peated every two weeks. Dose modifications for hemato-
logic toxicity were made on the basis of counts on the day
of treatment. For a white blood count = 3,500 cells/ul or
a platelet count = 100,000 platelets/ul – patients received
full doses of all three drugs as described above. For a white
blood count between 3,000 and 3,500 cells/ul and a plate-
let count = 100,000 platelets/ul, a 50% dose reduction of
all three drugs was performed. For white blood counts less
than 3,000 cells/ul and a platelet count < 100,000 plate-
lets/ul – all therapy was held until the counts had fully re-
covered (white blood count = 3,500 cells/ul and a platelet
count = 100,000). Patients experiencing a white blood
count = 2,000 and/or a platelet count = 75,000 any time
during therapy subsequently received 50% of the calculat-
ed dose even if the counts fully recovered.
Weekly complete blood counts, including platelet counts
and white blood count differentials were conducted to de-
termine the level of myelosuppresion. Before every other
cycle of treatment (q 4 weeks), a chest x-ray and complete
chemistry panel including electrolytes and serum creati-
nine were obtained. All lesions were measured bidimen-
sionally and assessed for changes by either an imaging
study (computed tomography, chest x-ray, ultrasound) or
by clinical examination to determine response to therapy.
Treatment was continued until disease progression be-
came evident or side effects became intolerable.
Statistical Methods
This study was planned to recruit 50 evaluable patients, al-
lowing us to estimate objective tumor response to within
+/- 15% with 95% confidence. Additional patients were
subsequently accrued to increase the precision of our esti-
mates of response and survival. The trial was conducted
with one interim analysis after nine evaluable patients. If
no patient had experienced an objective tumor response,
the study would have been terminated. The two-stage de-
sign used in this study was first proposed by Ed Gehan in
1961 (Gehan E.A. The determination of the number of pa-
tients required in a preliminary and a follow-up trial of a
new chemotherapeutic agent. J. Chron. Dis. 13:346–353,
1961). The probability of observing no responses was less
than 5% if the true response was 30% or greater. Progres-
sion-free survival was defined as the time from study entry
to the first observation of disease progression or death asBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/9
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a result of any cancer. Survival was defined as the time of
study entry until death as a result of any cause. These time-
to-event parameters were summarized using Kaplan-Mei-
er product-limit estimates. Log rank tests were used to as-
sess which factors were univariately predictive of the time
to progression and survival, and the Cox proportional
hazards regression model was used to assess which factors
were jointly predictive of these outcomes. The statistical
analysis was performed using the SAS package, version
6.12 (SAS Institute, Cary, NC).
Results
From August of 1987 through September of 1988, 97 pa-
tients were accrued to this study with two patients subse-
quently found to be ineligible. Data was not collected for
the first patient due to a protocol violation and a second
patient was found to have an ovarian primary cancer after
enrollment. Patient characteristics for the 95 eligible pa-
tients are listed in table 1. The median age was 64. The me-
dian ECOG performance score was 1. All patients had a
histologic diagnosis of adenocarcinoma. The major sites
of metastatic disease were liver, lung, soft tissue and
lymph node. None of the patients remain on study; 71 pa-
tients progressed on study, 16 patients were removed
from study either at the discretion of the treating physi-
cian or patient refusal to continue treatment, 3 patients
were removed from study due to toxicity, 2 patients ex-
pired while receiving therapy. Three patients were re-
moved for other reasons; one patient failed to adhere to
the treatment schedule, one relocated, and a third patient
never received therapy due to rapid medical decline.
Treatment and Response
A total of 1257 cycles of treatment were delivered during
the trial (median 9 cycles; range 0 to 41 cycles). Table 2 re-
flects the average percent of ideal dose given at each select-
ed cycle of treatment. Even after 25 cycles of therapy, at
least 75% of the ideal doses for all drugs were being ad-
ministered. Ninety-three of the 95 eligible patients en-
rolled onto the study were assessable for toxicity.
Mucositis, nausea/vomiting and diarrhea were the most
commonly observed toxicities and are listed in table 3.
The hematologic toxicities are also shown in table 3 and
in general were infrequently observed. Overall the regi-
men was well tolerated.
Figure 1
Treatment SchemaBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/9
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Of the 90 patients evaluable for response, ten patients
(11%) demonstrated a complete response of their disease
(median response duration 14.3 months). Remarkably, 3
of the 10 patients remain alive, 2 without evidence of dis-
ease with 51, 73 and 138 months of follow-up, respective-
ly. An additional 18 patients (20%) attained partial
responses; 16 have died of progressive disease while 2 pa-
tients are alive and without disease progression. Table 4
reflects the overall best response for the entire patient co-
hort.
The overall estimated median time to progression was 5.6
months. The estimated progression free survival at 12
months was 25.5% (standard error 4.5%). The overall es-
timated median survival time was 13.0 months. The esti-
mated survival rate at 12 months was 53.7% (standard
error 5.1%). Table 5 reflects overall survival for various
subgroups of patients. The prognostic factors found to be
significant on univariate analysis were ECOG perform-
ance score, gender and number of metastatic sites. Female
patients, patients with fewer metastatic sites and patients
with an ECOG performance 0 had a statistically signifi-
cant improved survival. Survival by metastatic site is
shown in Table 6. Those patients without lung metastasis
and those without intra-abdominal metastasis had longer
survival times. In the multivariate analysis, presence of
lymph nodes, lower LDH levels female sex, better per-
formance status and fewer metastatic sites were statistical-
ly predictive of longer survival (Data not shown).
Discussion
The rationale, at least in part, for this phase II study comes
from pre-clinical data suggesting MTX and LV potentiate
the anti-tumor activity of 5-FU. The cytotoxic effects of 5-
FU are mediated through inhibition of DNA and/or RNA
synthesis.[33] DNA synthesis inhibition is mediated by
the binding of the active 5-FU metabolite 5-fluoro-2'deox-
yuridine – 5-monophosphate (F-dUMP) to the enzyme
Table 1: Patient Characteristics
Total Patients 95 100%
Median Age Years (range) 64 (34–84)
Sex
Female 49 52%
Male 46 48%
Race
African American 21 22%
Caucasian 74 78%
Primary Disease
Colon 82 86%
Rectal 13 14%
Performance Status
03 5 3 7 %
15 2 5 5 %
28 8 %
Table 2: Percent of Ideal Dose (mean ± SD)
Course # of 
Patients
% Methotrex-
ate
% Leucov-
orin
% 5-FU
19 49 8 . 9   ± 7.2 99.9 ± 0.7 98.8 ± 10.3
5 76 90.1 ± 18.9 91.8 ± 17.4 86.3 ± 24.4
10 48 88.6 ± 19.9 87.8 ± 20.2 84.7 ± 44.2
15 34 90.3 ± 19.8 93.5 ± 16.4 89.0 ± 19.7
20 25 83.0 ± 24.2 89.7 ± 19.3 84.3 ± 22.9
25 15 76.7 ± 28.2 80.7 ± 26.7 77.2 ± 28.7
Table 3: Toxicity
Hematologic Toxic-
ity
# of 
Patients
Grade 
II (%)
Grade 
III (%)
Grade IV 
(%)
Toxicity
Neutropenia 93 10% 1% 0%
Thrombocytopenia 93 8% 0% 0%
Anemia 93 18% 4% 0%
Non Hematologic Toxicity
Diarrhea 93 17% 8% 0%
Mucositis 93 30% 8% 1%
Nausea/Vomiting 93 9% 11% 1%
Table 4: Best Objective Response
Response # of Patients (%) 
(n = 90 evaluable)
95% C. I.
Complete 10 (11%) 5.5 – 19.5
Partial 18 (20%) 12.3 – 29.8
Complete/Partial 28 (31%) 21.8 – 41.7
Stable Disease 33 (37%) 26.8 – 47.5
Progressive Disease 29 (32%) 22.8 – 42.9BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/9
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thymidylate synthetase (TS). This binding is enhanced by
high concentrations of reduced folate cofactors.[34] Al-
though this ternary complex is covalent, it dissociates with
a half-life of 2–3 hours in the absence of excess 5, 10-
methylene tetrahydrofolate. Thus high levels of 5, 10-
methylene tetrahydrofolate derived from LV not only al-
lows optimum ternary complex formation, but also pre-
vents subsequent breakdown of the complex.[35]
Additional in vitro studies suggest cells may need pro-
longed exposure to reduced folates in order to obtain
maximum inhibition of TS by FdUMP.[36] A second ob-
served means of potentiating the cytotoxic effects of 5-FU
is through the pre-treatment of cells with MTX. MTX-in-
duced enhancement of 5-phosphoribosyl-1-pyrophos-
phate (PRPP) pools with subsequent increased synthesis
of 5-FU nucleotides and incorporation of 5-fluoriuridine
– 5'-triphosphate (FUTP) into RNA has been proposed as
the basis for this biochemical modulation. [37–39] Sub-
sequent in vivo studies using fluorine 19 magnetic reso-
nance spectroscopy confirmed a three-fold increase in 5-
fluoronucleotide (FNuct), the active 5-FU metabolite, fol-
lowing the pre-treatment of animals with MTX [32]. These
observed changes in 5-FU catabolism resulted in a greater
anti-tumor activity than MTX given alone or MTX given af-
ter 5-FU. Consistent with these pre-clinical studies, the de-
sign of this phase II trial involved a fluorouracil infusion
that was initiated one hour into the 2 hour high dose in-
fusion of LV and 36 hours after the initial methotrexate
dosing.
Table 5: Subgroup analysis of survival
Characteristic # of Patients # Deaths Median Survival 
(months)
Log rank p-value
Overall 95 90 13.0
Age
= 60 40 40 12.4 .1170
> 60 55 50 13.9
Sex
Female 49 44 15.8 .0113
Male 46 46 12.1
Race
African American 21 20 14.8 .5929
Caucasian 74 70 12.6
Performance Status
0 35 32 17.9 .0001
1 50 50 11.4
28 8 4 . 8
LDH
= 230 44 41 15.4 .1255
> 230 47 45 10.8
Alkaline Phosphatase
= 130 48 46 14.3 .1732
> 130 46 43 12.3
Table 6: Outcome in relation to sites of metastatic disease
Site of Metastasis # of 
Patients
Median Survival (mo.) p – value
Lung
No 64 13.1 .0474
Yes 31 11.9
Liver
No 24 14.7 .5114
Yes 71 12.7
1 Intra-abdominal
No 59 17.1 .0043*
Yes 36 9.3
Lymph Nodes
No 85 13.2 .3319
Yes 10 12.5
# of Metastasis
1 49 17.1 .0009*
2 35 10.9
31 1 6 . 5
1Intra-abdominal metastasis refers to disease involving the colon, rec-
tum, pancreas, abdominal wall, bladder, prostate, pelvis or adrenals.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/9
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Our phase II study provides long-term efficacy and safety
data for sequential MTX-LV-5-FU chemotherapy adminis-
tered on a 14-day cycle. The 31% response rate and medi-
an survival duration (median 13.0 months) observed in
this trial are slightly improved when compared to the re-
sults reported for intravenous 5-FU therapy. Overall, treat-
ment with sequential MTX-LV-5-FU was very well-
tolerated. Grade III diarrhea was seen in only 8% of pa-
tients, grade III and IV mucositis in 8% and 1% of patients
respectively and grade III and IV nausea/vomiting in 11%
and 1% of patients respectively. The most common hema-
tologic toxicity observed was grade II and III anemia in
18% and 4% of patients respectively.
Other similar studies have shown comparable results in
terms of the efficacy and safety of MTX-LV-5-FU for pa-
tients with advanced colorectal cancer [44–48]. In a meta
analysis of eight randomized trials of 5-FU/MTX versus 5-
FU alone, the complete and partial response rates for the
5-FU patient cohort was 10% compared with 19% for pa-
tients receiving MTX/5-FU.[14] In addition, the median
survival was improved for patients receiving MTX/5-FU,
10.7 months versus 9.1 months for patients receiving 5-
FU alone (p = .024). Marsh et al. in a randomized trial, re-
ported a statistical improvement in response, time to pro-
gression (9.9 months versus 5.9 months) and median
survival (15.3 months versus 11.4 months) when the in-
terval between the MTX and 5-FU infusion was increased
from 1 hour to 24 hours.
Conclusions
We suggest our results and the pre-clinical and clinical
data discussed indicate the sequence of administration of
5-FU with MTX and LV is important. Future studies com-
bining 5-FU with other cytotoxic / biologic compounds
should consider the mechanism of the interaction and in-
corporate that information into the design of the trial.
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